Key Highlights

● DXCM shares ended 9 October 2026 at $84.11.

● Market data consensus target is $91.96, implying about 9.3% upside.

● The second data set shows a mean of $96.23 and a median of $95.

● JPMorgan lifted its target from $90 to $105 on 1 October.

DexCom (NASDAQ:DXCM), a constituent of both the S&P 500 and the Nasdaq-100, closed at $84.11 on Friday 9 October 2026. Target increases have dominated the past three months, and Barclays upgraded the shares on 7 October.

What Is the Latest Analyst Price Target?

Market data reports a consensus 12-month price target of $91.96 from 24 analysts, with a high of $115 and a low of $75, implying upside of about 9.3%. The second data set shows a higher mean of $96.23, a median of $95, a high of $115 and a low of $79 from 29 analysts, implying about 14%. The recent named targets average roughly $94, between the two.

What Are Wall Street Analysts Saying?

Market data counts three Strong Buy, nineteen Buy and two Hold ratings, with no Sell ratings. Recent named actions include Barclays upgrading on 7 October 2026, RBC raising its target from $90 to $105 on 1 October, Truist from $93 to $102 and TD Cowen reiterating $95 on 18 September, and Argus raising from $86 to $96 on 4 August. After the late July results, JPMorgan raised its target from $65 to $82, Mizuho and Stifel moved to $95, and Baird set $105.

What Could Help the Stock Reach the Price Target?

Target increases have dominated the past three months, and the upgrade from Barclays on 7 October is a recent positive. Market data reports quarterly revenue of $1.31bn, up 13.1% year on year, with earnings per share ahead of consensus. If growth holds, analysts could keep lifting estimates. The consensus target suggests upside of about 9.3% from the closing price.

What Could Prevent the Stock Reaching the Target?

Market data shows revenue growth slowed from 15.0% in the prior quarter to 13.1%, according to market data. JPMorgan, rating the shares Neutral, still holds a target of $82, below the consensus.

What Should Investors Watch Next?

Further broker updates following the Barclays upgrade may also be informative, since the average target can change when a single broker revises or drops its forecast.

DexCom's Run of Target Increases

DexCom closed at $84.11 on 9 October 2026, with the market data consensus of $91.96 implying about 9.3% upside. JPMorgan, rating the shares Neutral, still holds a target of $82, below the consensus.